Kerri-Ann Millar
Director of Finance/CFO bij CUE BIOPHARMA, INC.
Vermogen: 29 412 $ op 31-03-2024
Profiel
Kerri-Ann Millar is currently the Chief Financial Officer at Cue Biopharma, Inc. since 2020.
Prior to this, she worked as a Controller at Flexion Therapeutics, Inc. from 2014 to 2017.
She completed her undergraduate degree at Boston University in 1992.
Bekende belangen in openbare bedrijven
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
CUE BIOPHARMA, INC.
0.03% | 06-03-2024 | 15 562 ( 0.03% ) | 29 412 $ | 31-03-2024 |
Actieve functies van Kerri-Ann Millar
| Bedrijven | Functie | Begin |
|---|---|---|
| CUE BIOPHARMA, INC. | Director of Finance/CFO | 30-04-2018 |
Eerdere bekende functies van Kerri-Ann Millar
| Bedrijven | Functie | Einde |
|---|---|---|
| FLEXION THERAPEUTICS, INC. | Comptroller/Controller/Auditor | 01-09-2017 |
Opleiding van Kerri-Ann Millar
| Boston University | Undergraduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 1 |
|---|---|
| CUE BIOPHARMA, INC. | Health Technology |
| Bedrijven in privébezit | 1 |
|---|---|
Flexion Therapeutics, Inc.
 Flexion Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Flexion Therapeutics, Inc. operates as a biopharmaceutical company, which engages in the development and commercialization of novel and local therapies. It specializes in the treatment of patients with musculoskeletal conditions including osteoarthritis. It offers products under the Zilretta brand, an extended-release corticosteroid approved to manage osteoarthritis knee pain. The company was founded by Michael D. Clayman and Neil Bodick on November 5, 2007 and is headquartered in Burlington, MA. | Health Technology |
